Zoetis (ZTS) Q4 FY25 earnings call

Earnings call· Dec 2025 (Q4 FY25)· Health Care· Feb 12, 2026

Source: earnings call transcript

Zoetis delivered solid Q4 FY25 results, achieving 6% full-year organic operational revenue growth, driven by strong international performance and a diversified portfolio. Despite U.S. macroeconomic and competitive pressures impacting companion animal therapeutic visits and OA pain product sales, the company maintained its growth trajectory. Management is focused on disciplined execution, leveraging its robust pipeline, and optimizing channel strategies to navigate evolving market dynamics and sustain long-term value creation.

You’re reading a preview. Opening the full call uses 1 concall credit.

ZTS operating KPIs by quarter

ZTS operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Dec 2024 Q4 FY24	Jun 2025 Q2 FY25	Change vs prior quarter
Patients Librela	1.2M+ Librela, now entering its second year in the market, generated $53 million, growing 21% on the quarter and reaching more than 1.2 million patients. Source: earnings call transcript	1M And today, we are reaching just 1 million of them. Source: earnings call transcript	—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.